This study is being done to find out if treatment with the combination of immunotherapy drugs nivolumab and ipilimumab is better or worse than the usual approach for recurrent glioblastoma with elevated mutational burden.
Learn more about the Alliance-A071702 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
